Harmony Biosciences Q3 Earnings Miss Signals Potential Growth Deceleration

What happened

Harmony Biosciences reported Q3 2026 EPS of $0.81, missing the Zacks consensus of $1.00 and falling below the year-ago $0.87, with revenues also lagging estimates. The shortfall marks a departure from the high-teens growth and margin expansion that underpinned the prior thesis, suggesting either slower WAKIX patient adds, increased rebating, or higher operating costs. While the company's net cash position and WAKIX exclusivity through at least 2030 provide a buffer, the magnitude of the miss raises questions about the durability of its growth algorithm. The stock had already recovered from 2025 lows but remains below the mid-$40s target range implied by the base case, and this earnings disappointment may pressure the multiple further. Management will need to provide clarity on the drivers of the miss and revised guidance to restore confidence, with particular attention to WAKIX volume and net price.

Implication

Over a 12–18 month horizon, if the miss reflects transient factors like one-time rebate adjustments or launch timing, the thesis of undervalued WAKIX growth remains intact; however, if it indicates structural payor pushback or margin erosion, the base-case fair value of $42 may be too high, and the stock could drift toward the bear case of $30. Investors should monitor quarterly patient adds, net price realization, and opex growth, and reassess the investment case accordingly.

Thesis delta

The new data point challenges the assumption of sustained high-teens WAKIX growth and low-20s net margins. The thesis shifts from a confident 'potential buy' to a more cautious stance, requiring validation that the miss was temporary.